Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar

Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 295:2164–2167. 2006.

Leenhardt L, Grosclaude P and Cherie-Challine L: Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 14:1056–1060. 2004. View Article : Google Scholar

Williams ED, Abrosimov A, Bogdanova T, Demidchik EP, Ito M, LiVolsi V, Lushnikov E, Rosai J, Tronko MD, Tsyb AF, Vowler SL and Thomas GA: Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid. 18:847–852. 2008. View Article : Google Scholar

Hunt JL: Radiation induced thyroid diseases. Pathol Case Rev. 14:224–230. 2009. View Article : Google Scholar

Nakachi K, Hayashi T, Hamatani K, Eguchi H and Kusunoki Y: Sixty years of follow-up of Hiroshima and Nagasaki survivors: cancer progress in molecular epidemiology studies. Mutat Res. 659:109–117. 2008.PubMed/NCBI

Williams D: Radiation carcinogenesis: lessons from Chernobyl. Oncogene. 27:9–18. 2009. View Article : Google Scholar

Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, et al: Thyroid carcinoma. J Natl Compr Canc Netw. 3:404–457. 2005.PubMed/NCBI

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI and Tuttle RM: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 16:109–142. 2006. View Article : Google Scholar

Mazzaferri EL: Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract. 6:469–476. 2000. View Article : Google Scholar : PubMed/NCBI

Mazzaferri EL and Kloos RT: Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463. 2001. View Article : Google Scholar : PubMed/NCBI

Tanaka K, Sonoo H, Hirono M, Ohkubo S, Nomura T, Ikeda M, Nakajima K and Kurebayashi J: Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma. Surg Today. 35:714–719. 2005. View Article : Google Scholar : PubMed/NCBI

Chan JK: Papillary carcinoma of thyroid: classical and variants. Histol Histopathol. 5:241–257. 1990.PubMed/NCBI

Lang BH, Lo CY, Chan WF, Lam AK and Wan KY: Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg. 30:752–758. 2006. View Article : Google Scholar : PubMed/NCBI

Keelawat S and Poumsuk U: Association between different variants of papillary thyroid carcinoma and risk-group according to AMES (age, metastasis, extent and size) classification system. J Med Assoc Thai. 89:484–489. 2006.

Michels JJ, Jacques M, Henry-Amar M and Bardet S: Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 38:212–219. 2007. View Article : Google Scholar : PubMed/NCBI

Mazzaferri EL: Managing small thyroid cancers. JAMA. 295:2179–2182. 2006. View Article : Google Scholar : PubMed/NCBI

Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI

Fagin JA: Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol. 16:903–911. 2002.PubMed/NCBI

Bongarzone I and Pierotti MA: The molecular basis of thyroid epithelial tumorigenesis. Tumori. 89:514–516. 2003.PubMed/NCBI

Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocrine Pathology. 13:3–16. 2002. View Article : Google Scholar : PubMed/NCBI

Tallini G: Molecular pathobiology of thyroid neoplasms. Endocr Pathol. 13:271–288. 2002. View Article : Google Scholar : PubMed/NCBI

Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM and Fletcher JA: PAX8- PPARgamma1 fusion oncogene in human thyroid carcinoma. Science. 289:1357–1360. 2000. View Article : Google Scholar : PubMed/NCBI

McIver B, Grebe SK and Eberhardt NL: The PAX8/PPARgamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 4:221–234. 2004. View Article : Google Scholar : PubMed/NCBI

Nikiforova MN and Nikiforov YE: Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar : PubMed/NCBI

Garnett MJ and Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004. View Article : Google Scholar : PubMed/NCBI

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI

Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K and Takenoshita S: BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 22:6455–6457. 2003. View Article : Google Scholar : PubMed/NCBI

Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454–1457. 2003.

Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T and Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 88:4393–4397. 2003. View Article : Google Scholar : PubMed/NCBI

Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R and Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 22:4578–4580. 2003. View Article : Google Scholar : PubMed/NCBI

Xu X, Quiros RM, Gattuso P, Ain KB and Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63:4561–4567. 2003.PubMed/NCBI

Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI

Pritchard C and McMahon M: Raf revealed in life-or-death decisions. Nat Genet. 16:214–215. 1997. View Article : Google Scholar : PubMed/NCBI

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI

Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM and McCubrey JA: Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle. 9:1629–1638. 2010. View Article : Google Scholar : PubMed/NCBI

Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192–222. 2011.PubMed/NCBI

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2:135–164. 2011.PubMed/NCBI

Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J and Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 18:813–822. 1999. View Article : Google Scholar : PubMed/NCBI

Ciampi R and Nikiforov YE: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 148:936–941. 2007. View Article : Google Scholar : PubMed/NCBI

Santoro M, Melillo RM and Fusco A: RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 155:645–653. 2006. View Article : Google Scholar : PubMed/NCBI

Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and Malaponte G: Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI

Steelman LS, Navolanic PM, Franklin RA, Bonati A, Libra M, Stivala F, Martelli AM and McCubrey JA: Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). Mol Med Report. 1:139–160. 2008.PubMed/NCBI

Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI

Dhillon AS and Kolch W: Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell. 5:303–304. 2004. View Article : Google Scholar : PubMed/NCBI

Hubbard SR: Oncogenic mutations in B-Raf: some losses yield gains. Cell. 116:764–766. 2004. View Article : Google Scholar : PubMed/NCBI

McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, et al: Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 226:2762–2781. 2011. View Article : Google Scholar : PubMed/NCBI

Lima J, Trovisco V, Soares P, Máximo V, Magalhães J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, et al: BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab. 89:4267–4271. 2004. View Article : Google Scholar : PubMed/NCBI

Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM and Sobrinho-Simões M: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 202:247–251. 2004. View Article : Google Scholar : PubMed/NCBI

Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA and Greco A: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 23:7436–7740. 2004. View Article : Google Scholar : PubMed/NCBI

Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU and Komminoth P: BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer. 11:855–860. 2004. View Article : Google Scholar

Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, et al: BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 89:2414–2420. 2004. View Article : Google Scholar : PubMed/NCBI

Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA and Nikiforov YE: Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 115:94–101. 2005. View Article : Google Scholar : PubMed/NCBI

Fusco A, Viglietto G and Santoro M: A new mechanism of BRAF activation in human thyroid papillary carcinomas. J Clin Invest. 115:20–23. 2005. View Article : Google Scholar : PubMed/NCBI

Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE and Fagin JA: Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65:4238–4245. 2005. View Article : Google Scholar : PubMed/NCBI

Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF and Fagin JA: Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 66:6521–6529. 2006. View Article : Google Scholar : PubMed/NCBI

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D and Fagin JA: Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res. 12:1785–1793. 2006. View Article : Google Scholar : PubMed/NCBI

Liu D, Liu Z, Condouris S and Xing M: BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab. 92:2264–2271. 2007. View Article : Google Scholar : PubMed/NCBI

Salvatore G, Falco V, Salerno P, Nappi T, Pepe S, Troncone G, Carlomagno F, Melillo R, Wilhelm SM and Santoro M: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res. 12:1623–1629. 2006. View Article : Google Scholar : PubMed/NCBI

Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L and Fagin JA: Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 65:2465–2473. 2005. View Article : Google Scholar : PubMed/NCBI

Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, et al: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 115:1068–1081. 2005. View Article : Google Scholar : PubMed/NCBI

Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, et al: Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 24:6646–6656. 2005. View Article : Google Scholar

Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D and Umbricht CB: Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 90:4011–4018. 2005. View Article : Google Scholar : PubMed/NCBI

Hu S, Liu DX, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, et al: Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 119:2322–2329. 2006. View Article : Google Scholar : PubMed/NCBI

Hou P, Liu D and Xing M: Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer. 18:687–697. 2011. View Article : Google Scholar : PubMed/NCBI

Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, et al: Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab. 90:3028–3035. 2005. View Article : Google Scholar : PubMed/NCBI

Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B and Apte SS: A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 74:853–862. 1996. View Article : Google Scholar : PubMed/NCBI

Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A and Anand-Apte B: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 9:407–415. 2003. View Article : Google Scholar : PubMed/NCBI

Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, Yang KD, Cheng JT, Huang CC and Liu RT: miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 20:489–494. 2010. View Article : Google Scholar : PubMed/NCBI

Cahill S, Smyth P, Denning K, Flavin R, Li J, Potratz A, Guenther SM, Henfrey R, O’Leary JJ and Sheils O: Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer. 6:212007. View Article : Google Scholar : PubMed/NCBI

Yoon H, He H, Nagy R, Davuluri R, Suster S, Schoenberg D, Pellegata N and Chapelle AL: Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int J Cancer. 121:767–775. 2007. View Article : Google Scholar : PubMed/NCBI

Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K and Yamashita S: BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kB activation. Endocrinology. 147:5699–5707. 2006. View Article : Google Scholar : PubMed/NCBI

Karin M: Nuclear factor-kB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI

Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:9–34. 2006. View Article : Google Scholar

Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM and Shong M: Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 91:3667–3670. 2006. View Article : Google Scholar : PubMed/NCBI

Grabellus F, Worm K, Schmid KW and Sheu-Grabellus SY: The BRAF V600E mutation in papillary thyroid carcinomas is associated with glucose transporter 1 (GLUT1) overexpression. Thyroid. 22:377–382. 2012. View Article : Google Scholar : PubMed/NCBI

Nilsson M: Iodide handling by the thyroid epithelial cell. Exp Clin Endocrinol Diabetes. 109:13–17. 2001. View Article : Google Scholar : PubMed/NCBI

Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M and Filetti S: Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol. 145:129–135. 2001. View Article : Google Scholar : PubMed/NCBI

Ringel MD, Anderson J, Souza SL, Burch HB, Tambascia M, Shriver CD and Tuttle RM: Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol. 14:289–296. 2001. View Article : Google Scholar : PubMed/NCBI

Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, et al: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 92:2840–2843. 2007. View Article : Google Scholar : PubMed/NCBI

Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, Mazzarotto R, Casara D, Nacamulli D, Mantero F, et al: Molecular characteristics in papillary thyroid cancers (PTCs) with no (131)I uptake. Clin Endocrinol. 68:108–116. 2008. View Article : Google Scholar : PubMed/NCBI

Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P and De Micco C: Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. Endocr Relat Cancer. 13:485–495. 2006.PubMed/NCBI

Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M and Santisteban P: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na⁺/I⁻targeting to the membrane. Endocr Relat Cancer. 13:257–269. 2006. View Article : Google Scholar : PubMed/NCBI

Liu D, Hu S, Hou P, Jiang D, Condouris S and Xing M: Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 13:1341–1349. 2007. View Article : Google Scholar : PubMed/NCBI

Ikuyama S, Niller HH, Shimura H, Akamizu T and Kohn LD: Characterization of the 5-flanking region of the rat thyrotropin receptor gene. Mol Endocrinol. 6:793–804. 1992.PubMed/NCBI

Yokomori N, Tawata M, Saito T, Shimura H and Onaya T: Regulation of the rat thyrotropin receptor gene by the methylationsensitive transcription factor GA-binding protein. Mol Endocrinol. 12:1241–1249. 1998. View Article : Google Scholar : PubMed/NCBI

Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW and Sidransky D: Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 63:2316–2321. 2003.PubMed/NCBI

Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C and Dammann R: CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid. 16:633–642. 2006. View Article : Google Scholar : PubMed/NCBI

Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI

Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N and Yamashita S: Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer. 120:196–200. 2007. View Article : Google Scholar

Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW and Nikiforov YE: Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 30:216–222. 2006. View Article : Google Scholar

Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L and Beck-Peccoz P: BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol. 61:239–243. 2004. View Article : Google Scholar : PubMed/NCBI

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, et al: Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 13:455–464. 2006. View Article : Google Scholar : PubMed/NCBI

Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR and Lloyd RV: BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 15:136–143. 2006. View Article : Google Scholar : PubMed/NCBI

Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 246:466–471. 2007. View Article : Google Scholar : PubMed/NCBI

Kim KH, Kang DW, Kim SH, Seong IO and Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 45:818–821. 2004. View Article : Google Scholar : PubMed/NCBI

Kim KH, Suh KS, Kang DW and Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto’s thyroiditis. Pathol Int. 55:540–545. 2005.

Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ and Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 63:588–593. 2005. View Article : Google Scholar : PubMed/NCBI

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ and Shong YK: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf). 65:364–368. 2006. View Article : Google Scholar : PubMed/NCBI

Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D and Hoon DS: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 244:799–804. 2006. View Article : Google Scholar : PubMed/NCBI

Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC and Cheng JT: No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf). 63:461–466. 2005. View Article : Google Scholar : PubMed/NCBI

Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P and Basolo F: Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 92:4085–4090. 2007. View Article : Google Scholar : PubMed/NCBI

Lee JH, Lee ES, Kim YS, Won NH and Chae YS: BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology. 38:201–204. 2006. View Article : Google Scholar : PubMed/NCBI

Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D and Mitsiades N: Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther. 6:1070–1078. 2007. View Article : Google Scholar : PubMed/NCBI

Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI

Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, Park do J and Cho BY: Analysis of differential BRAF (V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer. 107:1831–1838. 2006. View Article : Google Scholar

Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A and Giordano C: BRAF(V600E) mutation and p27(kip1) expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases. Cancer. 110:1218–1226. 2007.PubMed/NCBI

Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lushnikov E, Kumagai A, Nakashima M, Meirmanov S, et al: The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 25:1729–1735. 2004.PubMed/NCBI

Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, et al: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 446:589–595. 2005.PubMed/NCBI

Xing M, Westra WH, Tufano RP, et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379. 2005. View Article : Google Scholar : PubMed/NCBI

Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M and Thomas G: Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol. 205:558–564. 2005. View Article : Google Scholar : PubMed/NCBI

Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G and Vitale M: Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 154:341–348. 2006. View Article : Google Scholar : PubMed/NCBI

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et al: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 15:191–205. 2008. View Article : Google Scholar : PubMed/NCBI

Cañadas Garre M, López de la Torre Casares M, Becerra Massare P, López Nevot MÁ, Villar Del Moral J, Muñoz Pérez N, Vílchez Joya R, Montes Ramírez R and Llamas Elvira JM: BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. Endocrinol Nutr. 58:175–184. 2011.PubMed/NCBI

Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D’Cruz A and Rajan MG: BRAF (V600E) Mutation in papillary phyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol. 23:83–93. 2012. View Article : Google Scholar : PubMed/NCBI

Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS and Bae JS: Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 203:436–441. 2011. View Article : Google Scholar : PubMed/NCBI

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H and Youn YK: BRAF(V600E) mutation is associated with tumor aggressiveness in papillary thyroid cancer. Word J Surg. 36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI

Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D and Westra WH: BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol. 17:1359–1363. 2004. View Article : Google Scholar : PubMed/NCBI

Quiros RM, Ding HG, Gattuso P, Prinz RA and Xu X: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 103:2261–2268. 2005. View Article : Google Scholar : PubMed/NCBI

Takano T, Ito Y, Hirokawa M, Yoshida H and Miyauchi A: BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer. 96:1549–1553. 2007. View Article : Google Scholar : PubMed/NCBI

Ito Y, Yoshida H, Maruo R, et al: BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathologic features and disease-free survival of patients. Endocrine J. 56:89–97. 2009. View Article : Google Scholar : PubMed/NCBI

Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE and Yip L: Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 18:3566–3571. 2011.

Ain KB: Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab. 14:615–629. 2000. View Article : Google Scholar : PubMed/NCBI

Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park do J, Lee HS, Cho BY, Lee ES and Kim SW: Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 65:660–666. 2006. View Article : Google Scholar : PubMed/NCBI

Patel A, Klubo-Gwiezdzinska J, Hoperia V, Larin A, Jensen K, Bauer A and Vasko V: BRAF(V600E) mutation analysis from May-Grünwald Giemsa-stained cytological samples as an adjunct in identification of high-risk papillary thyroid carcinoma. Endocr Pathol. 22:195–199. 2011.

Rowe LR, Bentz BG and Bentz JS: Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal. 3:102006. View Article : Google Scholar : PubMed/NCBI

Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, Pinchera A and Bevilacqua G: A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 19:837–842. 2009. View Article : Google Scholar

Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M and Arcila M: BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: Impact on diagnosis and prognosis. Acta Cytol. 55:563–569. 2011. View Article : Google Scholar : PubMed/NCBI

Bollag G, Hirth P, Tsai J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 467:596–569. 2010. View Article : Google Scholar : PubMed/NCBI

Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, et al: B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA. 107:10649–10654. 2010. View Article : Google Scholar : PubMed/NCBI

Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V and Parangi S: A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 19:1077–1084. 2009. View Article : Google Scholar : PubMed/NCBI

Liu D, Liu Z, Jiang D, Dackiw AP and Xing M: Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab. 92:4686–4695. 2007. View Article : Google Scholar

Henderson YC, Fredrick MJ and Clayman GL: Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. Arch Otolaryngol Head Neck Surg. 133:810–815. 2007. View Article : Google Scholar : PubMed/NCBI

Wallace EM, Lyssikatos JP, Yeh T, Winkler JD and Koch K: Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem. 5:215–229. 2005. View Article : Google Scholar : PubMed/NCBI

Wang D, Boerner SA, Winkler JD and LoRusso PM: Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta. 1773:1248–1255. 2007. View Article : Google Scholar : PubMed/NCBI